Cardio Diagnostics Holdings, Inc.

CDIO Healthcare Biotechnology

Cardio Diagnostics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14,800.00, down 57.6% from fiscal 2024. In the quarter to June 2026, revenue fell 28.0%, EPS grew 47.4% and free cash flow grew 15.6%, each against the same quarter a year earlier.

1.69 0.07 −3.98%
Market cap
$5.2M
P/E
0.0×
Fwd P/E
−0.6×
Dividend yield
—
F-score
3/9
Altman Z
−3.61
Beneish M
−3.53
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— — 3 3
ROE
(110.70%) (78.62%) (65.59%) (75.44%)
ROA
(98.75%) (70.70%) (60.91%) (70.62%)
ROIC
(227.44%) (217.55%) (227.16%) (219.40%)
Return on Tangible Assets
(90.08%) (108.02%) (84.08%) (100.86%)
Average Days of Receivables
258.73 198.42 93.98 97.50
Free Cash Flow per Share
(3.38) (3.38) (2.14) (1.97)
Free Cash Flow
(5.95) (5.91) (6.07) (5.82)
Other line items

Show all line items

Columns are period end dates